A Method to Correct for Radioactivity in Large Vessels That Overlap the Spine in Imaging-Based Marrow Dosimetry of Lumbar Vertebrae
暂无分享,去创建一个
[1] W. Bolch,et al. Correlations of total pelvic spongiosa volume with both anthropometric parameters and computed tomography-based skeletal size measurements. , 2006, Cancer biotherapy & radiopharmaceuticals.
[2] S. Shen,et al. Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[3] S. Strand,et al. Evaluation of methods for red marrow dosimetry based on patients undergoing radioimmunotherapy , 2005, Acta oncologica.
[4] J. Bouček,et al. Validation of prospective whole-body bone marrow dosimetry by SPECT/CT multimodality imaging in 131I-anti-CD20 rituximab radioimmunotherapy of non-Hodgkin’s lymphoma , 2005, European Journal of Nuclear Medicine and Molecular Imaging.
[5] J. Schlom,et al. Effects of Adjuvant Chelator or Chemotherapy on Dosimetry of 90Y-CC49 in Lung Cancer Patients Using 111In-CC49 as a Tracer , 2004 .
[6] J. Vose,et al. Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma. , 2004, Blood.
[7] J. Schlom,et al. A novel monoclonal antibody design for radioimmunotherapy. , 2003, Cancer biotherapy & radiopharmaceuticals.
[8] S. Shen,et al. Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting (90)Y-antibody therapy. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[9] W. Bolch,et al. Considerations of anthropometric, tissue volume, and tissue mass scaling for improved patient specificity of skeletal S values. , 2002, Medical physics.
[10] Wesley E Bolch,et al. Considerations of marrow cellularity in 3-dimensional dosimetric models of the trabecular skeleton. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[11] Y. Erdi,et al. Red marrow dosimetry for radiolabeled antibodies that bind to marrow, bone, or blood components. , 2000, Medical physics.
[12] Daniel H. S. Silverman,et al. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin’s lymphoma , 2000, European Journal of Nuclear Medicine.
[13] G. Denardo,et al. Prediction of myelotoxicity using radiation doses to marrow from body, blood and marrow sources. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[14] S. Larson,et al. Bone marrow dosimetry: regional variability of marrow-localizing antibody. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[15] S. Shen,et al. Estimation of Radiation Absorbed Doses to the Red Marrow in Radioimmunotherapy , 1995, Clinical Nuclear Medicine.
[16] G Sgouros,et al. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[17] J. Schlom,et al. Dose fractionation of radiolabeled antibodies in patients with metastatic colon cancer. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[18] G. Denardo,et al. Biology of radionuclide therapy , 1989 .
[19] R. E. Lee,et al. Sacral scintigraphy for bone marrow dosimetry in radioimmunotherapy. , 1989, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.